Curated news and analysis on clinical trials, drug approvals, and medical research.
PCF invests $6.3M in 31 Young Investigator Awards, supports Creativity Awards, and hosts Home Run Challenge 2026 to raise awareness. The foundation has contributed to 15 FDA-approved therapies over its 30-year history.
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
Grünenthal has successfully completed a Phase I trial for its proprietary nociceptin receptor (NOP) agonist, demonstrating safety and tolerability in 113 healthy volunteers. The company plans to advance the novel pain therapy into a Phase II trial later this year, with results expected in the second half of 2027.
A phase 2 clinical trial published in The Lancet Gastroenterology & Hepatology found that dupilumab significantly improved symptoms and biological markers in patients with eosinophilic gastritis, a rare stomach disease with no approved treatments. The DEGAS study involved 41 patients across 11 U.S. centers.
Actor Eric Dane died of ALS at age 53 in February 2026, less than a year after announcing his diagnosis. Former NFL star Chris Johnson also revealed his ALS diagnosis at age 39. The cases highlight the neurodegenerative disease, which affects about 33,000 people in the U.S. and has no cure.
All 12 Rett syndrome patients treated with Taysha's TSHA-102 gene therapy in the REVEAL Phase 1/2 trial achieved at least one developmental milestone within one year, with functional gains continuing up to 30 months. The company has completed dosing in the Phase 3 portion and expects top-line data and FDA feedback in early 2027.
Two recent court decisions impact pharmaceutical trade secret litigation. A U.S. District Court dismissed a lawsuit by PTC Therapeutics against former employees, finding no plausible allegation of misappropriation. Separately, the Federal Circuit ruled that it retains jurisdiction over trade secret claims even after voluntary dismissal of patent claims, providing defendants with a clearer path to appellate review.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.
Bio-Techne Corp shares have surged approximately 37% over the past month as institutional investors adjust their holdings in the Minnesota-based life sciences company. The company surpassed quarterly revenue expectations with $295.88 million, while recently divesting Exosome Diagnostics to focus on higher-margin core segments.
Law enforcement in Oklahoma and California have reported results from separate drug investigations, leading to multiple arrests and seizures. The Oklahoma case involved a nearly two-year undercover operation resulting in 20 people charged across 66 criminal cases related to methamphetamine and fentanyl. California authorities arrested several suspects and seized significant quantities of fentanyl and methamphetamine in two distinct investigations.
ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.
Japanese researchers have completed the Phase I clinical trial of TRG035, a drug targeting the USAG-1 protein to regrow teeth. The therapy aims to treat congenital tooth agenesis, with Phase II trials in Japan planned and a goal of practical use by 2030.
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
The Trump administration is withholding federal funds for Second Avenue Subway Phase 2 over a naming dispute, potentially delaying critical construction contracts. The MTA states the $1.3 billion-saving project will serve 100,000 daily riders and create 70,000 jobs. If funds aren't restored by March, it could impede excavation work at 106th and 125th Streets.
The Gyrolab automated immunoassay platform from Gyros Protein Technologies addresses reproducibility and throughput challenges in biotherapeutic development for ADCs and bispecifics. Case studies show measurable improvements in assay consistency and efficiency for titer and impurity testing workflows.
Cosmo Pharmaceuticals reported positive 12-month Phase III data for Clascoterone 5% topical solution in male androgenetic alopecia, showing sustained hair growth and a safety profile comparable to vehicle. A separate metabolomics study characterized key inflammatory markers in scalp seborrheic dermatitis, identifying Malassezia fungi and specific free fatty acids as central drivers of the condition.
Cell and gene therapy manufacturing is shifting from scientific feasibility toward industrialization, with industry leaders emphasizing process consolidation, closed workflows, and digital quality systems to enable scalable, reproducible production. Insights from the Advanced Therapies USA conference highlighted that sustainable CGT commercialization depends on manufacturability at scale, with a US$40 million grant program and single-workflow bioreactor data demonstrating practical steps toward that goal.
Otsuka's ADHD drug centanafadine met the primary endpoint in a Phase 3b trial in adults with comorbid anxiety, with results supporting its efficacy ahead of a July 24, 2026 FDA decision. The FDA has granted priority review to the New Drug Application for the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). If approved, centanafadine would be a novel treatment option for ADHD in children, adolescents, and adults.
